Set to the tune of the Beatles’ song, “Let It Be”, we present words of wisdom from the Third Quarter (Q3). These words of wisdom were not whispered, as in the “Let It Be” song lyrics, but spoken confidently with precise experimental facts by Assoc Prof, Dr. Richard Gordon…
EpicentRx is elated despite this newsletter being belated. It’s already the end of July - how time does fly! The unquestioned highlight of Q2 – and possibly of all 2024 – was the BOOM! heard ‘round the world from Dr. Anthony P. Conley’s ASCO oral presentation on the...
This being a leap year, EpicentRx leapt into action in Q1. In January, which is named after the two-faced Roman God, Janus, who focused simultaneously on the past and the future, EpicentRx made sure to look back even as it moved forward. February, the leap month, was...
The drive to 2025 is underway! With 2023 in the rear-view mirror, we at EpicentRx look ahead not only to 2024 but also to 2025 when we expect top-line data from five key EpicentRx clinical trials to read out. For lead FDA Fast Tracked small molecule, RRx-001...
A busy Fall “leaves” little to no downtime for EpicentRx Summer slowdown? What summer slowdown? EpicentRx kicked off the Fall season in high gear with continuing preparations for the start of a large Phase 2b follow on study called KEVLARx with nibrozetone (RRx-001)...
As you may have noticed, EpicentRx is a company on the move. From the award of FDA Fast Track status for RRx-001 as an anti-oral mucositis agent to invited talks at premier venues like the AD/PD conference in Gothenburg, Sweden and the World Parkinson Congress in...